Quentis Therapeutics is a developer of immuno-therapeutics designed to address ER stress in multiple diseases.
Quentis Therapeutics is a developer of immuno-therapeutics designed to address ER stress in multiple diseases. The company's therapeutics are designed to target ER stress pathways and awaken the immune system's ability to fight cancer, enabling patients to get access to new treatments for cancer.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 3, 2018 | Grant | $1M | 1 | New York City Economic Development Corporation - NYCEDC | — | Detail |
Feb 27, 2018 | Series A | $48M | 7 | Polaris Partners Versant Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
New York City Economic Development Corporation - NYCEDC | Yes | Grant |
Polaris Partners | Yes | Series A |
Versant Ventures | Yes | Series A |
AbbVie Biotech Ventures | — | Series A |
Alexandria Venture Investments | — | Series A |
New York Ventures | — | Series A |
Taiho Pharmaceutical Co | — | Series A |
Yonghua Capital | — | Series A |